Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

AEMCOLO

RIFAMYCIN SODIUM

Standard Dose
EQ 194MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview AEMCOLO is listed in Drugs@FDA under application 210910 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient RIFAMYCIN SODIUM Form and strength TABLET, DELAYED RELEASE;ORAL - EQ 194MG BASE Sponsor COSMO TECHNOLOGIES Submission history Latest submission status date: 2019-07-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview AEMCOLO is listed in Drugs@FDA under application 210910 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient RIFAMYCIN SODIUM Form and strength TABLET, DELAYED RELEASE;ORAL - EQ 194MG BASE Sponsor COSMO TECHNOLOGIES Submission history Latest submission status date: 2019-07-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
AEMCOLO (RIFAMYCIN SODIUM) | Drug Monograph | MedicHelpline